person · Reporting owner
Polymeropoulos Mihael Hristos
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | Director · President and CEO · Chairman of the Board | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vanda Pharmaceuticals Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,704,496 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Sale · Disposed 156,235 · Balance 2,704,496 F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.08 to $8.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.08 to $8.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 23:51 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 156,235 | $8.17 | $1,276,971.15 |
DisclosureSEC source: 0001355537-26-000002 · ownership.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,704,496 F1 · shares: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.08 to $8.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:46 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 525,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-059770 · ownership.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,860,731 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2027, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| August 07, 2025 Filed Aug 8, 2025 20:05 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | PurchaseCommon Stock | 10,000 | $4.15 | $41,500.00 |
DisclosureSEC source: 0000950170-25-105819 · ownership.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,335,731 Read SEC document |
| May 21, 2025 Filed May 22, 2025 01:23 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | PurchaseCommon Stock | 481 | $4.39 | $2,111.59 |
DisclosureSEC source: 0000950170-25-076012 · ownership.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,325,731 Read SEC document |
| May 21, 2025 Filed May 22, 2025 01:23 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | PurchaseCommon Stock | 9,519 | $4.40 | $41,883.60 |
DisclosureSEC source: 0000950170-25-076012 · ownership.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,325,250 Read SEC document |
| May 16, 2025 Filed May 19, 2025 21:13 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | PurchaseCommon Stock | 20,000 | $4.22 | $84,472.00 |
DisclosureSEC source: 0000950170-25-074565 · ownership.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,315,731 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.22 to $4.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| March 06, 2025 Filed Mar 6, 2025 22:53 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | PurchaseCommon Stock | 5,000 | $5.01 | $25,050.00 |
DisclosureSEC source: 0000950170-25-034966 · ownership.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,295,731 Read SEC document |
| March 06, 2025 Filed Mar 6, 2025 22:53 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | PurchaseCommon Stock | 5,000 | $5.02 | $25,100.00 |
DisclosureSEC source: 0000950170-25-034966 · ownership.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,290,731 Read SEC document |
| March 05, 2025 Filed Mar 5, 2025 22:19 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | PurchaseCommon Stock | 5,000 | $5.03 | $25,150.00 |
DisclosureSEC source: 0000950170-25-033845 · ownership.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,285,731 Read SEC document |
| March 05, 2025 Filed Mar 5, 2025 22:19 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | PurchaseCommon Stock | 5,000 | $5.01 | $25,050.00 |
DisclosureSEC source: 0000950170-25-033845 · ownership.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,280,731 Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:45 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | PurchaseCommon Stock | 10,000 | $4.71 | $47,050.00 |
DisclosureSEC source: 0000950170-25-032276 · ownership.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,275,731 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.69 to $4.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:45 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Tax withholdingCommon Stock | 95,999 | $4.76 | $456,955.24 |
DisclosureSEC source: 0000950170-25-032276 · ownership.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,265,731 F1 · shares: Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Read SEC document |
| February 28, 2025 Filed Feb 28, 2025 22:30 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | PurchaseCommon Stock | 10,000 | $4.76 | $47,600.00 |
DisclosureSEC source: 0000950170-25-030176 · ownership.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,361,730 Read SEC document |
| February 27, 2025 Filed Feb 27, 2025 21:13 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | PurchaseCommon Stock | 10,000 | $4.76 | $47,600.00 |
DisclosureSEC source: 0000950170-25-029059 · ownership.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,351,730 Read SEC document |
| February 26, 2025 Filed Feb 26, 2025 21:46 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | PurchaseCommon Stock | 5,000 | $4.78 | $23,900.00 |
DisclosureSEC source: 0000950170-25-027860 · ownership.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,341,730 Read SEC document |
| February 26, 2025 Filed Feb 26, 2025 21:46 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | PurchaseCommon Stock | 5,000 | $4.75 | $23,750.00 |
DisclosureSEC source: 0000950170-25-027860 · ownership.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,336,730 Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 00:38 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | PurchaseCommon Stock | 10,000 | $4.46 | $44,640.00 |
DisclosureSEC source: 0000950170-25-027056 · ownership.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,331,730 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.445 to $4.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 00:45 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 450,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-024489 · ownership.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,321,730 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2026, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 21:47 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 24,288 | $4.13 | $100,273.01 |
DisclosureSEC source: 0000950170-24-027256 · ownership.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,871,730 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.12 to $4.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 21:47 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 30,884 | $4.24 | $131,065.52 |
DisclosureSEC source: 0000950170-24-027256 · ownership.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,896,018 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.22 to $4.275, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:52 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 450,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-018030 · ownership.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,926,902 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2025, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 23:25 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 22,538 | $6.25 | $140,876.02 |
DisclosureSEC source: 0001209191-23-016462 · doc4.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,476,902 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.20 to $6.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:25 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 22,426 | $6.23 | $139,718.47 |
DisclosureSEC source: 0001209191-23-016462 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,499,440 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.21 to $6.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:10 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $7.05 | $0.00 |
DisclosureSEC source: 0001209191-23-011341 · doc4.xml · derivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2033-02-15 F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 16, 2024, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:10 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 115,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011341 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,521,866 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2024, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| December 06, 2022 Filed Dec 7, 2022 22:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionStock Option (Right to Buy) · Derivative | 75,365 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0001209191-22-060227 · doc4.xml · derivative · entry 6 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,635 shares Expires 2022-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option fully vested and exercisable. Read SEC document |
| December 06, 2022 Filed Dec 7, 2022 22:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 48,250 | $10.61 | $512,082.08 |
DisclosureSEC source: 0001209191-22-060227 · doc4.xml · nonDerivative · entry 4 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,406,866 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 6, 2022 as reflected in this Form 4. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.39 to $10.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| December 06, 2022 Filed Dec 7, 2022 22:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 75,365 | $3.12 | $235,138.80 |
DisclosureSEC source: 0001209191-22-060227 · doc4.xml · nonDerivative · entry 3 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,455,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 22:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionStock Option (Right to Buy) · Derivative | 74,635 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0001209191-22-060227 · doc4.xml · derivative · entry 5 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,365 Underlying: Common Stock · 74,635 shares Expires 2022-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option fully vested and exercisable. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 22:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 47,650 | $10.62 | $506,200.25 |
DisclosureSEC source: 0001209191-22-060227 · doc4.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,379,751 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 6, 2022 as reflected in this Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.43 to $10.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 22:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 74,635 | $3.12 | $232,861.20 |
DisclosureSEC source: 0001209191-22-060227 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,427,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 02:27 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 29,588 | $11.15 | $329,944.66 |
DisclosureSEC source: 0001209191-22-015157 · doc4.xml · nonDerivative · entry 3 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,352,766 F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.08 to $11.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 02:27 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 7,508 | $11.19 | $84,014.52 |
DisclosureSEC source: 0001209191-22-015157 · doc4.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,382,354 F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:27 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $11.36 | $0.00 |
DisclosureSEC source: 0001209191-22-015157 · doc4.xml · derivative · entry 4 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2032-02-27 F4 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 28, 2023, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:27 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 115,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015157 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,389,862 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2023, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:31 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 71,676 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-21-067592 · doc4.xml · derivative · entry 6 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,676 shares Expires 2021-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in 48 equal monthly installments beginning on January 6, 2012. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:31 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 46,200 | $16.00 | $739,347.84 |
DisclosureSEC source: 0001209191-21-067592 · doc4.xml · nonDerivative · entry 4 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,274,862 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 5, 2021 as reflected in this Form 4. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.70 to $16.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:31 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 71,676 | $4.88 | $349,778.88 |
DisclosureSEC source: 0001209191-21-067592 · doc4.xml · nonDerivative · entry 3 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,321,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 21:31 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 78,324 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-21-067592 · doc4.xml · derivative · entry 5 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,676 Underlying: Common Stock · 78,324 shares Expires 2021-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in 48 equal monthly installments beginning on January 6, 2012. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 21:31 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 50,000 | $16.49 | $824,275.00 |
DisclosureSEC source: 0001209191-21-067592 · doc4.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,249,386 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 5, 2021 as reflected in this Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.10 to $16.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 21:31 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 78,324 | $4.88 | $382,221.12 |
DisclosureSEC source: 0001209191-21-067592 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,299,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 22:15 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 175,000 | $18.00 | $3,150,052.50 |
DisclosureSEC source: 0001209191-21-019118 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,221,062 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 23:41 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 15,206 | $18.34 | $278,902.37 |
DisclosureSEC source: 0001209191-21-017276 · doc4.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,396,062 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.26 to $18.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:41 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 7,479 | $18.45 | $138,002.51 |
DisclosureSEC source: 0001209191-21-017276 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,411,268 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.32 to $18.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:18 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantEmployee Stock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $20.28 | $0.00 |
DisclosureSEC source: 0001209191-21-014878 · doc4.xml · derivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-02-23 F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 24, 2022, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:18 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 115,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-014878 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,418,747 F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| December 15, 2020 Filed Dec 15, 2020 21:24 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 46,663 | $0.00 Strike: $8.75 | $0.00 |
DisclosureSEC source: 0001209191-20-063474 · doc4.xml · derivative · entry 9 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,663 shares Expires 2020-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested in 48 equal monthly installments from the date of grant. Read SEC document |
| December 15, 2020 Filed Dec 15, 2020 21:24 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 39,150 | $13.00 | $508,844.30 |
DisclosureSEC source: 0001209191-20-063474 · doc4.xml · nonDerivative · entry 6 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,303,747 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 15, 2020 as reflected in this Form 4. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.85 to $13.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| December 15, 2020 Filed Dec 15, 2020 21:24 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 46,663 | $8.75 | $408,301.25 |
DisclosureSEC source: 0001209191-20-063474 · doc4.xml · nonDerivative · entry 5 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,342,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 21:24 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 61,520 | $0.00 Strike: $8.75 | $0.00 |
DisclosureSEC source: 0001209191-20-063474 · doc4.xml · derivative · entry 8 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,663 Underlying: Common Stock · 61,520 shares Expires 2020-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested in 48 equal monthly installments from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.